Chair

Chair

Mabel Toribio, MD

MGH

Safety and Efficacy of Once-Daily Osilodrostat in Cushing’s Syndrome to Improve Cortisol Circadian Rhythm and Quality of Life: A Multi-Center Study

Andrea M Isidori, PhD, MD

Sapienza University of Rome

Chair

Kevin Choong Ji Yuen, MD, FRCP (UK), FACE

Barrow Neurological Institute

CAM2029 Octreotide Subcutaneous Depot Maintains Control of IGF-I and Symptoms of Acromegaly Across the 4-Week Dosing Interval and During Intervals Greater Than 28 Days: Data from the ACROINNOVA 1 Trial

Monica R Gadelha, MD, PhD

Neuroendocrinology Research Center/Endocrinology Division, Medical School and Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro

Clofutriben, an 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, vs Placebo in a Phase II Trial for ACTH-dependent Cushing’s Syndrome (RESCUE)

Maria Fleseriu, MD

Oregon Health & Science University

Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension

Beverly M. K. Biller, MD

Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital

Effects of Relacorilant on Body Weight and Body Composition in Patients With Endogenous Hypercortisolism in the Phase 3 GRACE and GRADIENT Studies

Oksana Hamidi

University of Texas Southwestern Medical Center

Development of a Novel Growth Hormone Receptor Antagonist Antibody for the Treatment of Acromegaly

Ethan J Weiss, MD

Marea Therapeutics, Inc.

New evidence of growth hormone treatment benefit on bone mineralization during transition from paediatric to adult care in a growth hormone deficient French cohort

Philippe A Touraine, MD,PhD

GH Pitie Salpetriere

The Role of Late-Night Salivary Cortisol in Evaluating Endocrine Remission in Patients With Cushing’s Disease Following Pituitary Radiotherapy: A Retrospective Cohort Analysis

Ukasha Habib, MD

Harvard Medical University